Viking therapeutics aktie

Cookie Einstellungen. Marketing- und Statistik-Cookies kommen nicht zum Einsatz.

Up to The Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints, with patients receiving VK demonstrating statistically significant reductions in body weight compared with placebo. Additionally, the study showed VK treatment to be safe and well tolerated with the majority of treatment emergent adverse events TEAEs being categorized as mild or moderate. Patients receiving weekly doses of VK demonstrated statistically significant reductions in mean body weight after 13 weeks, ranging up to Patients receiving VK also demonstrated statistically significant reductions in mean body weight relative to placebo, ranging up to

Viking therapeutics aktie

.

No evidence of a plateau was observed at Week 13 for any VK dose, suggesting further weight loss might be achieved from extended dosing periods.

.

Viking Therapeutics, Inc. The company was founded by Brian Lian and Michael A. This browser is no longer supported at MarketWatch. For the best MarketWatch. Market Data. Latest News All Times Eastern scroll up scroll down. What can I do? She deducted the entire loan from my inheritance. I need that money. What now?

Viking therapeutics aktie

Hier stellen wir 8 Kommentare aus der Community passend zu Viking Therapeutics vor, die von Nutzer:in als besonders interessant, informativ oder als gute Chartanalyse bewertet wurden. UTP Consolidated Nasdaq 3. NYSE 1. Tradegate Gettex London 8.

Americas got talent singers

The Phase 2 VENTURE trial was a randomized, double-blind, placebo-controlled study intended to evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of VK, administered subcutaneously, once weekly. Nachrichten Nachrichten Nachrichten auf FN. VK continues to demonstrate a promising efficacy and tolerability profile following 13 weeks of repeat dosing in obese subjects," said Brian Lian, Ph. Mean percent change from baseline 4,5. VK demonstrated encouraging safety and tolerability following 13 weeks of once-weekly dosing. Notes: Safety population, includes all randomized subjects who received at least one dose of study drug. Buying dips on the name lookin. Alle Aktienempfehlungen. Kursziel: -. Viking therapeutic is expensive to buy at current levels TradingView. The Relative Strength Index RSI of 65 indicates that the stock is currently close to the overbought territory, suggesting a strong momentum in the stock's price. Data from a Phase 1 and a Phase 2a trial evaluating VK dosed subcutaneously for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Semaglutide is a GLP-1 receptor agonist that has been approved by the U. However, investors may want to approach this stock with caution despite its impressive performance.

Conference Call Scheduled for Wednesday, February 7 at p. Eastern Time. The company will host a conference call to discuss financial results and general corporate updates beginning at p.

Aktien: This includes conditions like fatty liver disease and type 2 diabetes, which have been on the rise globally. Sektor: Gesundheit. PR Newswire Mean percent change from baseline 4,5. Kursziel: -. Patients receiving VK also demonstrated statistically significant reductions in mean body weight relative to placebo, ranging up to Kursziel: 5. Erweiterte Suche. No evidence of a plateau was observed at Week 13 for any VK dose, suggesting further weight loss might be achieved from extended dosing periods.